We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.85 | 6.70 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMVENN
RNS Number : 9163A
Venn Life Sciences Holdings PLC
29 March 2017
29 March 2017
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Issue of Equity
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that an application has been made by the Company to the London Stock Exchange and the Irish Stock Exchange for 45,000 new ordinary shares of nominal value of GBP0.001 each in the Company ("Ordinary Shares") to be admitted to trading on the AIM market of the London Stock Exchange and the ESM market of the Irish Stock Exchange. The new Ordinary Shares will rank in pari passu with the existing Ordinary Shares in issue.
The new Ordinary Shares are being issued in consideration of services rendered to the Company during 2016. Dealings are expected to commence in these new Ordinary Shares on at 8:00 a.m. on 4 April 2017.
Following admission of these new Ordinary Shares, Venn's issued share capital will consist of 60,284,263 Ordinary Shares.
Enquiries:
Venn Life Sciences Holdings Plc Allan Wood, Non-Executive Chairman Tony Richardson, Chief Executive Officer Tel: +353 1 5499341 Davy (Nominated Adviser and Broker) Fergal Meegan / Matthew de Vere Tel: +353 1 679 6363 White (Corporate Finance) Orla Bolger (Corporate Broking) Hybridan LLP (Co-Broker) Tel: +44 (0)20 3764 2341 Claire Louise Noyce Walbrook PR Ltd Tel: +44(0)20 7933 8787
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOESEIFEUFWSEID
(END) Dow Jones Newswires
March 29, 2017 08:57 ET (12:57 GMT)
1 Year Venn Life Sciences Chart |
1 Month Venn Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
